Clinical Trials Logo

Clinical Trial Summary

Cerebral amyloid angiopathy-related intracerebral (CAAH) hemorrhage is second factor of primary intracerebral hemorrhage. However, no effective prevention and treatment strategies have been established. Remote ischemic conditioning is a neuroprotective strategy. In animal studies,RIC is efficiency in accelerating the absorption of hematoma. Therefore, the investigators plan to carry out this research to evaluate the safety and efficacy of RIC in patients with CAA related ICH.


Clinical Trial Description

In China, primary intracerebral hemorrhage accounts for 80-85% of all types of intracerebral hemorrhage, while cerebral amyloid angiopathy-related intracerebral hemorrhage is the second factor, accounting for approximately 20-30%. It is often characterized by repeated and multifocal lobar hemorrhage, which will not only cause neurological deficit on the limbs, but also influence the cognitive level of patients and may even be life-threatening. At present, the role of surgery in CAA-related ICH is controversial, and there is no effective prevention and treatment strategies have been established. Additionally, it is always associated with a low rate of good prognosis(11%-60%) and a high risk of recurrent ICH (10%-60%). Thus, a novel approach which can improve the clinical outcome and reduce the risk of recurrent intracerebral hemorrhage is urgently needed. Remote ischemic conditioning (RIC) has been developed as a neuroprotective strategy to prevent and treat acute ischemic stroke and small cerebrovascular disease. Additionally, clinical research testified that RIC is safe and feasible for patients with subarachnoid hemorrhage. In animal studies, RIC is efficiency in accelerating the absorption of hematoma. Therefore, the investigators plan to carry out this research to evaluate the safety and efficacy of RIC in patients with CAA related ICH. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04757597
Study type Interventional
Source Capital Medical University
Contact Xunming Ji, MD PhD
Phone 010-83199430
Email jixm@ccmu.edu.cn
Status Recruiting
Phase N/A
Start date February 24, 2021
Completion date June 1, 2022

See also
  Status Clinical Trial Phase
Completed NCT05486897 - Periventricular White Matter Hyperintensities in Cerebral Amyloid Angiopathy and Hypertensive Arteriopathy
Recruiting NCT03969732 - Multimodal Biomarkers for Diagnosis and Prognosis in CAA Phase 3
Completed NCT03542656 - Application of Amyloid PET in Cerebral Amyloid Angiopathy Phase 3
Recruiting NCT04604587 - MRI-visible Enlarged Perivascular Spaces and the Alteration of Lymphatic Drainage System in CAA Phase 3
Completed NCT05565144 - Brain Hemorrhage and Functional Outcome in Stroke Patients With CAA Features on Pre-thrombolysis MRI Treated With Intravenous Thrombolysis (Thrombolysis in CAA) ( Thromb in CAA )
Active, not recruiting NCT03464344 - Cortical Superficial Siderosis and Risk of Recurrent Intracerebral Hemorrhage in Cerebral Amyloid Angiopathy. N/A
Completed NCT03824197 - Auburn University Research on Olive Oil for Alzheimer's Disease (AU-ROOAD) N/A
Active, not recruiting NCT01856699 - Superficial Siderosis in Patients With Suspected Cerebral Amyloid Angiopathy N/A
Recruiting NCT06128824 - High Frequency Imaging in Cerebral Amyloid Angiopathy
Completed NCT01821118 - Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy Phase 2
Completed NCT05394636 - Cerebellar Superficial Siderosis in Cerebral Amyloid Angiopathy
Recruiting NCT04204642 - SEarchiNg biomarkErs Cerebral Amyloid Angiopathy (SENECA)
Recruiting NCT05207475 - Safety and Efficacy of Remote Ischemic Conditioning on Cerebral Amyloid Angiopathy. (RIC-CAA) N/A
Not yet recruiting NCT02361411 - Methods of Etiological Diagnosis of Cerebral Amyloid Angiopathy N/A
Not yet recruiting NCT04654026 - the Safety and Efficacy of Antiplatelet Therapy in Patients of CAA
Completed NCT05082194 - Balance Eyesight and Muscle Tension in the Cervical Spine in Cerebral Amyloid Angiopathy
Completed NCT04825808 - Detailed Clinical and MRI Characteristics in Primary Non-traumatic Convexity Subarachnoid Haemorrhage Elderly Patients.
Recruiting NCT05680389 - Antibiotics Against Amyloid Angiopathy Phase 1/Phase 2
Recruiting NCT05734378 - Prognosis of Cerebral Small Vessel Disease
Withdrawn NCT01382849 - F-18-AV-45 Uptake, Spot Sign Presence and Cerebral Amyloid Angiopathy (CAA) in Primary Intracranial Hemorrhage (ICH) N/A